Do People With Hiv Who Have Attained Viral Suppression Need Art Still

Abstract

Groundwork

Studies in adults and children suggested that starting antiretroviral therapy (Fine art) soon after infection positively influences early events in HIV infection raising the possibility that remission may be accomplished in some.

Methods

Nosotros designed an analytic treatment suspension (ATI) trial to test the hypothesis that a sizable minority of HIV-infected neonates who initiated Fine art <fourteen days of birth and maintained on Fine art would exist able to maintain viral suppression when Art was withdrawn. To yield the target cohort for this trial, 73 HIV-infected neonates identified at one hospital in Johannesburg, Due south Africa, were initiated on Art <14 days of birth and maintained on Fine art tracking viral load (VL) refuse and immune recovery (clinicaltrials.gov # NCT02431975).

Findings

3 HIV-infected infants (4.1%) died and nine (12.3%) were lost to follow-up before 48 weeks of historic period. Of those surviving on study, 52.5% attained and sustained VL <50 copies/ml and half of these sustained CD4+ T-cell percentage >thirty% which were the primary entry criteria for the ATI trial. Proportions achieving ATI eligibility criteria were similar in the 46 infants starting ART <48 h (19.half dozen%) to 27 infants starting 2–xiv days (25.nine%) (p = 0.567).

Interpretation

Very early ART on its own, using regimens available when the trial was designed, is bereft to reach minimum entry criteria needed to justify our trial of ART interruption. Decisions about how quickly to start ART should exist based on optimizing standard clinical outcomes rather than with the expectation that remission can be attained.

Funding

NICHD /NIAID (U01HD080441), South African Enquiry Chairs Initiative of DST and NRF (South Africa).

Keywords

• HIV
• Neonate
• Antiretroviral therapy
• Remission

Research in context

Prove before this study

Our written report was designed presently after the report of the infant in Mississippi who started antiretroviral treatment (Fine art) within 30 h of birth and who was able to maintain viral suppression off treatment for over 2 years. This case study was consequent with studies of Fine art started soon afterward master HIV infection in adults that had observed that some individuals can achieve periods of post-treatment viral control when ART is withdrawn (remission). Taken together with knowledge from developmental biology of the neonatal immune profile, we hypothesized that starting and maintaining effective treatment in early life would lead to protection of disquisitional immune processes and establishment of smaller viral reservoirs, leading to remission in a sizable minority (>20%). Acceptable viral suppression and allowed competence while Fine art is maintained is generally taken as minimum criteria for Art suspension trials. Nosotros conducted a PubMed search, with no language restrictions, including the following search terms in combination: HIV, neonate, newborn, children, perinatal, antiretroviral therapy, cure, remission, treatment suspension, to place articles pertinent to our study through May 6, 2019.

Added value of this study

We started ART within 14 days of birth among 73 HIV-infected neonates identified inside 48 h of nascence at i hospital in Johannesburg, South Africa. Of those surviving on study, 52.v% attained and sustained viral load <50 copies/ml and half of these sustained CD4+ T-cell percentage >30%. Proportions achieving these virological and immunological endpoints were similar in the 46 infants who started Fine art <48 h to 27 infants starting 2–14 days.

Implications of all available evidence

Very early ART on its own, using the regimens available at the time our study was designed, is unlikely to exist sufficient to achieve remission in a sizable minority of infants. The rare cases of perinatally-infected children who take been able to achieve prolonged periods of remission too propose that early on handling may collaborate with host and viral factors to achieve remission merely ART on its ain may non be sufficient. Early on initiation of more potent antiretroviral regimens, long-acting formulations and/or alternative interventions, such as broadly-neutralizing antibodies, need to be investigated to enable more rapid and sustained viral control and immune recovery as a stepping stone to achieve remission in perinatally-infected infants.

1. Introduction

Studies in adults given antiretroviral therapy (Fine art) presently subsequently main infection accept observed that some individuals can achieve periods of post-treatment viral command when ART is withdrawn (remission) [

1

• Saez-Cirion A.
• Bacchus C.
• Hocqueloux L.
• Avettand-Fenoel 5.
• Girault I.
• Lecuroux C.
• et al.

Mail service-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS visconti study.

• Crossref
• PubMed
• Scopus (688)
• Google Scholar

,

2

• Stohr W.
• Fidler South.
• McClure Thou.
• Weber J.
• Cooper D.
• Ramjee G.
• et al.

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.

• Crossref
• PubMed
• Scopus (51)
• Google Scholar

,

,

four

• Lodi S.
• Meyer L.
• Kelleher A.D.
• Rosinska M.
• Ghosn J.
• Sannes M.
• et al.

Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.

• Crossref
• PubMed
• Scopus (85)
• Google Scholar

,

5

• Steingrover R.
• Pogany K.
• Fernandez Garcia E.
• Jurriaans S.
• Brinkman K.
• Schuitemaker H.
• et al.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

• Crossref
• PubMed
• Scopus (65)
• Google Scholar

,

6

• Namazi G.
• Fajnzylber J.M.
• Aga East.
• Bosch R.J.
• Acosta Due east.P.
• Sharaf R.
• et al.

The control of hiv after antiretroviral medication break (CHAMP) study: posttreatment controllers identified from 14 clinical studies.

• Crossref
• PubMed
• Scopus (73)
• Google Scholar

]. The written report of the baby in Mississippi who started handling within 30 h of birth and who was able to maintain viral suppression off treatment for over 2 years raised the tantalizing possibility that similar results might be observed in other early on treated infants [

]. Art started close to nascency is not just shut in time to acquisition of infection but is also being given during a developmentally-critical time flow when the immune arrangement is transitioning to a more mature grade and is at its virtually quiescent [

,

]. We hypothesized that starting and maintaining effective treatment in early on life would atomic number 82 to protection of critical immune parameters and establishment of smaller viral reservoirs, leading to remission in a sizable minority (>20%).

To exam the hypothesis, nosotros designed an analytic handling interruption (ATI) trial. Interruption of treatment is currently the simply known arroyo to test whether periods of remission can be accomplished. Hither we describe the cohort of HIV-infected neonates identified within 48 h of birth, started on ART within 14 days and maintained on ART, that we intended as the target population for this trial. We describe the proportions of these early-treated, HIV-infected children who come across virologic and immunologic eligibility criteria for entry into the ATI trial.

ii. Methods

2.i Study design

Nosotros designed an ATI trial to test the hypothesis that a sizable minority (>xx%) of HIV-infected neonates started on ART inside xiv days of birth and maintained on ART for at to the lowest degree ii years would be able to sustain viral suppression after ART withdrawal. To yield the target population for the ATI trial, nosotros established clinical protocols at Rahima Moosa Female parent and Child Hospital (RMMCH), Johannesburg, S Africa, a) to provide HIV diagnostic testing at birth to identify HIV-infected neonates with a positive upshot within 48 h of nascence and b) to initiate ART inside xiv days of birth and maintain Fine art to at least two years of historic period (clinicaltrials.gov # NCT02431975). RMMCH is a centrally-located, large urban public third hospital and 1 of the teaching facilities of the University of the Witwatersrand. Children who met virologic and immunologic endpoints would be eligible for entry into the ATI trial. The protocols were approved by the Institutional Review Boards (IRB) of the University of the Witwatersrand and Columbia Academy. Written informed consent was obtained from mothers for their ain and their infants' participation. In improver to IRB approval, the ATI trial protocol was developed in consultation with a Data Safety and Monitoring Board (DSMB) who met annually and monitored progress of the target cohorts' potential to enter the trial.

2.2 Participants

When the written report was initially proposed, we hypothesized that Fine art would need to exist initiated within 48 h of birth to have the later beneficial outcomes. For practical purposes, in order to start ART <48 h of nativity, a point-of-care neonatal diagnosis plan was established that used Xpert HIV-ane Qual (Cepheid, Sunnyvale, CA) [

]. The site already had a routine birth testing program sending samples to the national laboratory for diagnosis (HIV-one total nucleic acid (TNA) COBAS TaqMan HIV-1 Qualitative Exam Version ii·0 Roche Molecular Systems, Inc., Branchburg, NJ). Every bit part of the routine plan, all HIV-exposed neonates have blood nerveless by venipuncture after nascency prior to belch. When staff capacity permitted, ane of the vials from this claret collection was tested on-site using Xpert. Positive Xpert results were re-run with residual sample from the same blood collection. Neonates with two positive Xpert results were eligible for firsthand on-site Fine art initiation. The on-site testing protocol was intended to yield a cohort enriched with infants initiating Fine art <48 h subsequently birth although inclusion criteria for the ATI trial required only Art initiation <xiv days. Two clinical protocols were in place to recruit infants intended for the trial. These protocols included Xpert co-tested neonates as well every bit infants with positive or indeterminate results from the routine diagnosis program not co-tested with Xpert. The latter neonates were recalled to the site for ART initiation once routine results were bachelor.

2.3 Procedures

The initial ART regimen consisted of nevirapine, lamivudine and zidovudine. Nevirapine was inverse to lopinavir-ritonavir no sooner than 42 weeks mail service-menstrual historic period taking into account patient readiness. Drugs were given in liquid form twice daily. Either stavudine or abacavir were given in the upshot of zidovudine toxicity and abacavir substituted for zidovudine once infants were ≥3 months of age. Cotrimoxazole was started at 4–6 weeks of age. Routine infant prophylaxis was one dose of nevirapine every bit soon equally possible subsequently birth and daily nevirapine for six weeks after discharge. Infants considered high gamble had twice-daily zidovudine added. For infected neonates identified before discharge, prophylaxis was discontinued and the treatment regimen initiated. For the infected neonates recalled to the site, prophylaxis was discontinued once ART was initiated.

ART was initiated based on results of the first round of diagnostic testing. To confirm diagnosis, a second claret sample was collected prior to the first Art dose. For those co-tested with Xpert, confirmatory testing was usually done on the same day every bit initial testing. The qualitative HIV-1 TNA diagnostic PCR was repeated and viral load (VL) done (quantitative HIV-ane RNA COBAS AmpliPrep/COBAS TaqMan HIV-1 test, version 2·0, Roche Molecular Systems, Inc., Branchburg, NJ). If subsequent tests did not confirm HIV diagnosis, infants were excluded from eligibility for the ATI trial and were managed based on the profile of their results.

Fine art was continued for a minimum of 104 weeks. Infants were followed on ane of two protocols. The preferred protocol repeated VL tests at 1, 2 and 4 weeks of age, every 4 weeks to 24 weeks and so every eight weeks to 104 weeks. The culling protocol, repeated VL at 4, eight, 12, xvi, and 24 weeks then every 12 weeks to 104 weeks. Diagnostic HIV PCR tests were repeated at 24, 48, 72 and 104 weeks. CD4+ T-cell count and pct (TruCount Method, BD Biosciences, Deutschland) was measured at enrolment, 24, 48, 72 and 104 weeks. Consummate blood counts were washed at 4, 12, 24, 48, 72 and 104 weeks. Alanine aminotransferase (ALT) was measured at 16 weeks. Results were graded using the Division of AIDS toxicity tables [

[11]

• Avettand-Fenoel V.
• Hocqueloux L.
• Ghosn J.
• Cheret A.
• Frange P.
• Melard A.
• Viard J.P.
• Rouzioux C.

Total HIV-ane DNA, a marker of viral reservoir dynamics with clinical implications.

• Crossref
• PubMed
• Scopus (117)
• Google Scholar

]. All course 3 and four abnormalities were repeated. A maternal blood sample was nerveless at enrolment for VL, CD4+ T-prison cell count and complete blood count. Antenatal data and maternal HIV handling history was nerveless. Children were assessed for clinical progression at every visit and anthropometric data were nerveless.

two.4 Sample size

Power calculations adamant the need for 40 children to enter the ATI trial. Initially, it was anticipated that 60 early on-treated children would be sufficient to obtain this number based on the assumption that ~80% would become eligible for the interruption trial and ~85% of these would remain in care. As effect data accumulated, information technology was clear that the cohorts of early on-treated infants would need to exist larger and enrolment connected. A DSMB review in May 2022 ended that the numbers of early-treated children recruited would not be able to attain a target population of sufficient size to enter the ATI trial as originally designed. Further enrolment into the early on-treatment protocols ended presently thereafter.

ii.5 Outcomes

Here nosotros report the proportions of children in the early-treated cohorts who met the primary virologic and immunologic endpoints for consideration for entry into the ATI trial. The primary virologic endpoint was VL <400 copies/ml by 24 weeks after Fine art initiation and <50 copies/ml by 48 weeks of age and no confirmed VL (i.e. two sequent measurements) >50 copies/ml subsequently suppression was attained. The principal immunologic endpoint was a CD4+ T-cell percentage >30% by 24 weeks which was sustained through follow-up.

2.6 Statistical analysis

The analysis included children with confirmed HIV infection (start sample indicating HIV-infection collected <48 h) and Art initiated inside 14 days born between March ane, 2022 (beginning of prospective enrolment into the primeval written report protocol) and September 30, 2022 (to allow at least 48 weeks of follow-up data on all children). Follow-up information accrued through September 2022 or truncated at 104 weeks of age were utilized. The primary analysis describes proportions meeting eligibility criteria for the ATI trial. Binomial proportion confidence intervals were reported under 0.05 significance level. If cell counts for proportions were >10, Wald-type confidence intervals were reported; for counts ≤10, Clopper-Pearson estimation method was used. Secondary analyses compared proportions stratified by whether ART was initiated before or after 48 h of birth. Proportions were compared with Fisher's exact tests and continuous variables were compared with t-tests, if normally-distributed, in which case the means were shown, and with Wilcoxon signed-rank tests otherwise, in which case the medians were shown. Statistical analyses were conducted in SAS version nine.iv (Cary, NC).

3. Results

Between March 1, 2022 and September xxx, 2017, 7217 HIV-exposed neonates were tested with the routine diagnostic HIV PCR among which 4233 (59%) were co-tested with Xpert yielding 115 neonates with an initial positive or indeterminate result. From these, 79 confirmed infected infants were enrolled and 73 of these started Fine art within 14 days of birth (Fig. i).

Among 46 infants who started Fine art <48 h of birth, the screening blood sample was collected at a median of 13.0 h (interquartile range (IQR) ix.0–15.eight; range 2.0–31.1 h) after nascency; all only one after having received a dose of nevirapine as prophylaxis (median time of blood draw iii.3 h afterward prophylaxis [IQR 2.5–4.three; range 0.5–9.0 h]). The routine diagnostic PCR run on the same sample was positive in 41 and indeterminate in 5 (all turned positive on subsequent PCR tests). The 2d sample was drawn a median of 5.9 h (IQR 5.0–22.6) after the first sample a median of 22.half dozen h (IQR xviii.3–30.7) after birth. The median baseline VL was 35,071 copies/ml (IQR 5370–267,000; range 60–2445,950 copies/ml) (Tabular array 1).

Table ane Baseline characteristics of 73 HIV-infected neonates initiating antiretroviral therapy (ART) within fourteen days of life at Rahima Moosa Female parent and Child Hospital, Johannesburg, South Africa between March 1, 2022 and September xxx, 2017.

Characteristic	Total (N = 73)	Initiated Art <48 h (N = 46)	Initiated ART two–14 days (N = 27)	p-value
Sex, N (%)
Male	39 (53.4)	26 (56.five)	13 (48.2)	0.628
Female	34 (46.6)	xx (43.five)	14 (51.9)
Birth Weight (grams), Range	905–4150	1860–4150	905–3890
Nativity Weight (grams), Hateful (SD)	2820 (602)	2954 (477)	2592 (723)	0.026
Birth Weight (grams), North (%)
<2500	sixteen (21.9)	half dozen (thirteen.0)	ten (37.0)	0.075
2500–3000	29 (39.7)	twenty (43.5)	9 (33.3)
≥3000	28 (38.four)	20 (43.5)	viii (29.half-dozen)
Gestational age by Ballard (weeks), North (%)
≥37 weeks (term)	63 (86.3)	44 (95.6)	19 (lxx.4)	0.004
<37 weeks (pre-term)	x (13.7)	2 (4.iv)	8 (29.6)
Mode of commitment, Northward (%)
Vaginal	55 (75.3)	38 (82.six)	17 (63.0)	0.091
Caesarean	18 (24.vii)	8 (17.four)	ten (37.0)
Ever breastfed, N (%)
Yep	57 (78.i)	39 (84.viii)	18 (66.seven)	0.085
No	16 (21.ix)	7 (15.two)	9 (33.3)
Babe prophylaxis, N (%)
None	2 (2.7)	1 (two.2)	1 (3.7)
Nevirapine only	67 (91.viii)	45 (97.8)	22 (81.5)	0.016
Nevirapine + Zidovudine	4 (five.five)	0 (0.0)	4 (fourteen.eight)
Pre-handling Viral load (copies/ml), Median (IQR)	31,445 (5355–290,807)	35,071 (5370–267,000)	12,335 (1124–454,790)	0.780
Historic period when pre-treatment Viral load measured (days), Median (IQR)	1 (1–4)	1 (1–1)	vii (4–8)	<0.001
Pre-handling Viral load (copies/ml), North (%)
<400	9 (13.0)	5 (ten.nine)	4 (17.4)	0.271
400–g	4 (5.8)	3 (6.5)	1 (4.4)
1000–10,000	10 (14.5)	six (13.0)	4 (17.four)
ten,000–100,000	xx (29.0)	xiv (30.4)	6 (26.1)
100,000–1000,000	xviii (26.i)	15 (32.6)	3 (13.0)
≥1000,000	8 (eleven.6)	iii (vi.5)	5 (21.7)
Pre-treatment CD4+ T-cell count (cells/mm3), Median (IQR)	1823 (1474–2372)	1819 (1474–2442)	1875 (1182–2372)	0.926
Pre-treatment CD4+ T-cell percentage (%), Median (IQR)	40.6 (32.ii–49.8)	39.9 (32.ii–48.8)	47.4 (30.9–51.viii)	0.354
Pre-treatment CD4+ T-cell per centum (%), N (%)
<25 (severe)	6 (9.8)	3 (vii.ane)	3 (15.8)	0.296
25–30 (avant-garde)	half-dozen (9.8)	6 (fourteen.3)	0 (0.0)
thirty–35 (mild)	ix (xiv.viii)	6 (14.three)	3 (15.eight)
>35 (none or not meaning)	40 (65.6)	27 (64.3)	13 (68.four)
Mother age (years), Mean (SD)	28.4 (6.0)	28.4 (five.seven)	28.4 (6.vii)	0.976
Maternal antiretroviral therapy (Fine art) category, N (%)
ART started earlier pregnancy and continued	12 (xvi.4)	six (thirteen.0)	half-dozen (22.2)	0.276
ART started during pregnancy, ≥12 weeks	twenty (27.iv)	15 (32.6)	5 (18.5)
Fine art started during pregnancy, <12 weeks	25 (34.3)	xiv (30.4)	11 (twoscore.7)
Art started during pregnancy, unknown time	1 (1.4)	0 (0.0)	1 (three.7)
No ART up until delivery	xv (20.six)	11 (23.ix)	4 (xiv.8)
Maternal Fine art regimen at delivery, Due north (%)
Efavirenz-based	56 (76.7)	35 (76.i)	21 (77.eight)	0.134
Lopinavir-ritonavir-based	2 (2.vii)	0 (0.0)	2 (vii.iv)
No Fine art earlier commitment	15 (xx.6)	11 (23.ix)	4 (14.viii)
Maternal Viral load closest to nascency (copies/ml), Median (IQR)	38,459 (1760–104,538)	31,433 (1292–104,538)	50,400 (1760–125,515)	0.547
Maternal CD4+ T-cell count closest to nascence (cells/mmthree), Median (IQR)	327 (207–567)	357 (231–603)	259 (128–480)	0.097
Maternal CD4+ T-cell count closest to nascence (cells/mm3), N (%)
<200	17 (23.3)	eight (17.4)	9 (33.3)	0.500
200–349	23 (31.5)	fifteen (32.6)	8 (29.6)
350–499	13 (17.eight)	9 (19.6)	4 (xiv.8)
>500	twenty (27.4)	14 (30.four)	half dozen (22.2)

Denominators are every bit shown.

Abbreviations: Antiretroviral handling (ART), Standard departure (SD), Inter-quartile range (IQR).

• Open tabular array in a new tab

Among 27 infants who started ART >48 h and <xiv days of age (2–14 days), the screening blood sample was collected a median of 13.0 h (IQR 7.1–24.0; range 0.9–60.0 h) afterward nativity; in 66.7% of cases subsequently having received a dose of nevirapine (median time of blood draw 4.8 h after prophylaxis [IQR ii.8–6.3; range ii.0–vii.8 h]). All infants, except one, received at to the lowest degree i dose of nevirapine prophylaxis and were prescribed daily nevirapine on belch; 4 of these were prescribed zidovudine as well. Three infants were co-tested with Xpert just did not initiate ART on-site at the time and 24 infants had not been co-tested with Xpert on-site and had to exist recalled. One of the 27 infants had an indeterminate result on initial screening (Fig. i). The median baseline VL was 12,335 copies/ml (IQR 1124-454,790; range 102–8630,000 copies/ml) (Tabular array 1).

Among 46 neonates initiating ART <48 h of birth, nevirapine, lamivudine and zidovudine was initiated at a median of 24 h after birth (IQR 18.one–30.5; range viii.ane–48.0 h). Art initiation was a median of half dozen.4 h (IQR five.6-22.two; range 4.9–34.8 h) after the blood depict to identify infection. Among 27 neonates initiating Fine art 2–14 days of nascency, the median age at Art initiation was half-dozen days (IQR four–8 days). All, except one, initiated treatment with nevirapine, lamivudine and zidovudine (Table ii).

Table 2 Timing of antiretroviral therapy (ART) initiation and Fine art modifications among 73 infants identified every bit HIV-infected inside 48 h of life.

Characteristic	Total (N = 73)	Initiated Art <48 h (North = 46)	Initiated ART 2–14 days (N = 27)	p-value
Age at Art outset in days of life
Range	0–14	0–2	2–xiv
Mean (SD)	3.0 (3.two)	1.0 (0.5)	6.4 (2.9)
Median (IQR)	ane.0 (1.0–v.0)	1.0 (i.0–ane.0)	six.0 (four.0–eight.0)
Age at ART commencement in hours since birth
Range		eight.1–48.0 * Exact hours known in 41/45. In the other 4 known to be <48 h but exact numbers of hours non recorded.
Mean (SD)		25.one (10.5)
Median (IQR)		24.0 (xviii.1–30.5)
Initial regimen, North (%)
Nevirapine/Lamivudine/Zidovudine § 1 child received i dose of lopinavir-ritonavir in error at the starting time of treatment just then continued with nevirapine. Abbreviations: Antiretroviral handling (ART), Standard deviation (SD), Inter-quartile range (IQR), Post-menstrual age (PMA).	72 (98.6)	46 (100.0)	26 (96.iii)	0.370
Lopinavir-ritonavir/Lamivudine/Zidovudine	1 (one.4)	0 (0.0)	1 (three.seven)
Lopinavir-ritonavir status in 48 weeks of follow-upward, N (%)
Lost before age to switch	3 (4.1)	iii (six.five)	0 (0.0)	0.410
Initiated on lopinavir-ritonavir	1 (1.four)	0 (0.0)	1 (iii.vii)
Switched to lopinavir-ritonavir in first 28 days	34 (46.6)	21 (45.7)	13 (48.2)
Switched to lopinavir-ritonavir after 28 days	35 (48.ix)	22 (47.eight)	xiii (48.ii)
If switched in starting time 28 days, historic period switched (days)
Range	fourteen–32	14–xxx	18–32
Median (IQR)	21 (17–29)	18 (16–24)	28 (21–30)
If switched later on 28 days, age switched (days)
Range	29–132	29–71	34–132
Median (IQR)	44 (33–61)	35 (31–47)	57 (45–80)
Lopinavir-ritonavir switch in relation to estimated postal service-menstrual age (PMA), N (%)
No follow-upward	3 (4.1)	3 (6.five)	0 (0.0)	0.491
Initiated on lopinavir-ritonavir	ane (1.4)	0 (0.0)	1 (3.7)
Earlier 42 weeks PMA	two (2.7)	1 (ii.2)	1 (three.vii)
42 weeks PMA	25 (34.3)	16 (34.8)	ix (33.iii)
Afterwards 42 weeks PMA	42 (57.v)	26 (56.5)	16 (59.three)
Zidovudine changed to abacavir in 48 weeks of follow-up, N	33	21	12
If switched to abacavir, median historic period switched in days (IQR)	169 (125–198)	149 (125–186)	182 (130–260)
Zidovudine changed to stavudine in 48 weeks of follow-upwardly, Northward	four	2	2

Exact hours known in 41/45. In the other 4 known to exist <48 h merely verbal numbers of hours non recorded.

§ One child received 1 dose of lopinavir-ritonavir in fault at the start of treatment merely and then continued with nevirapine. Abbreviations: Antiretroviral treatment (Fine art), Standard deviation (SD), Inter-quartile range (IQR), Post-menstrual age (PMA).

• Open table in a new tab

Nevirapine was changed to lopinavir-ritonavir at a median of 30 days (IQR eighteen–36; range 14–71 days) in neonates who started Fine art <48 h and 33 days (IQR 28–57; range xviii–132 days) in neonates who started ART 2–14 days of life. In two infants this was sooner than the recommended 42 weeks, 34.three% at 42 weeks, and 57.5% > 42 weeks (Table 2). Two children with Grade iii neutropenia substituted stavudine for zidovudine at 14 and 74 days of age (both in the 2–xiv days group). One child with Grade three low hemoglobin substituted stavudine for zidovudine at 66 days of age (2–fourteen days grouping). All other Grade iii and four laboratory abnormalities resolved on repeat testing without a change in regimen (Supplementary Table i).

Three infants died at 43, 61 and 89 days of age. These 3 infants had started ART at <48 (exact time unknown), 28, and 44 h respectively. All three were male built-in at term, one was depression nascence weight, and two were cesarian section deliveries. All had high baseline VL and had transitioned to the lopinavir-ritonavir regimen, merely none attained viral suppression earlier expiry (Fig. 2).

Nine infants (12.3%) were lost to follow-up before 48 weeks of historic period: 8/46 who started ART <48 h and one/27 who started ii–xiv days. Taking into business relationship the 3 deaths, survival on written report was lower in those who started <48 h (35/46) compared to 2–xiv days (26/27) (p = 0.026).

Overall 63.0% (46/73) of children achieved <50 copies/ml past 48 weeks of age (45/46 achieved <400 copies/ml by 24 weeks) and 32/73 (43.8%) sustained VL <l copies/ml without a confirmed measurement above this threshold to 48 weeks or last follow-upward visit (32/61 [52.5%] of those remaining in follow-up). About infants (56/61; 91.8%) had CD4+ T-cell percent >30% during follow-up with 46/61 (75.4%) starting to a higher place this threshold. Xvi (26.2%) of 61 children remaining in follow-upwardly met both the virologic and immunologic criteria. At that place were no significant differences in the proportions meeting these benchmarks past age at ART initiation (Table 3).

Table 3 Proportion of 73 HIV-infected infants starting antiretroviral therapy (ART) within 14 days of nascency who met virologic and immunologic eligibility criteria for the analytic handling intermission study by age at Fine art initiation.

Characteristic	Total			Initiated ART <48 h			Initiated Art 2 to fourteen days			p-value
	Northward	% of total (95% CI) N = 73	% of those in follow-up (95% CI) Due north = 61	N	% of total (95% CI) Due north = 46	% of those in follow-upwards (95% CI) Due north = 35	N	% of full (95% CI) N = 27	% of those in follow-up (95% CI) N = 26
Deaths	3	4.1 (0.ix–11.5)		3	6.5 (1.4–17.9)		0	0 (0–12.8)		0.291 * Fisher Verbal examination results among all children (N = 73) comparing proportions betwixt two ART initiation groups.
Loss to Follow-up before 48 weeks	9	12.three (5.8–22.1)		eight	17.4 (vii.eight–31.iv)		one	three.7 (0–nineteen.0)		0.141 * Fisher Verbal test results among all children (N = 73) comparing proportions between two Art initiation groups.
Meets virologic criteria
No: VL not <50 copies/mL past 48 weeks	15	20.6		half dozen	13.0		9	33.3
No: VL <50 copies/mL achieved but confirmed rebound >50 copies/mL	14	19.2		11	23.9		three	11.i
Yes: VL achieved and sustained <50 copies/mL	32	43.8 (32.v–55.two)	52.5 (xl.0–65.0)	18	39.i (25.0–53.2)	51.four (34.9–68.0)	14	51.nine (33.0–lxx.seven)	53.9 (34.7–73.0)	0.335 * Fisher Exact test results among all children (North = 73) comparison proportions between two ART initiation groups.
Meets immunologic criteria
No	35			19			16
Yes: CD4+ T-cell% sustained >thirty%	26		42.vi (thirty.ii–55.0)	16		45.seven (29.2–62.2)	10		38.5 (19.8–57.2)	0.610 § Fisher Exact test results amongst surviving children (Northward = 61) comparing proportions betwixt two ART initiation groups Abbreviations: Antiretroviral treatment (ART), Confidence intervals (CI), Viral load (VL).
Virologic and immunologic criteria
Meets both	16	21.9 (12.4–31.four)	26.2 (xv.2–37.three)	9	19.6 (ix.iv–33.9)	25.7 (12.five–43.3)	7	25.9 (11.1–46.3)	26.9 (11.six–47.8)	i.000 § Fisher Exact test results amidst surviving children (Northward = 61) comparing proportions between two Fine art initiation groups Abbreviations: Antiretroviral treatment (ART), Conviction intervals (CI), Viral load (VL). 0.567 * Fisher Verbal test results among all children (Northward = 73) comparing proportions betwixt two Art initiation groups.
Meets virologic but non immunologic	16	21.nine	26.2	9	nineteen.6	25.vii	7	25.9	26.9
Meets immunologic simply not virologic	10	13.vii	16.iv	7	15.two	20.0	three	11.ane	11.v
Meets neither	19	26.0	31.2	x	21.7	28.vi	nine	33.3	34.6

Fisher Exact test results amongst all children (Northward = 73) comparing proportions betwixt two ART initiation groups.

§ Fisher Verbal exam results among surviving children (Due north = 61) comparison proportions betwixt two Fine art initiation groups Abbreviations: Antiretroviral handling (Fine art), Confidence intervals (CI), Viral load (VL).

• Open table in a new tab

The proportion of children with sustained CD4+ T-cell percentage >thirty% was not significantly college in those who met virologic criteria (16/32 [fifty.0%]) versus those who did not (10/29 [34.five%]) (p = 0.30). The proportion with sustained CD4+ T-cell count >g cells/mm³ was also not significantly higher in children who met virologic criteria (29/32 [90.6%]) versus those who did non (22/29 [75.9%]) (p = 0.17).

Applying more than stringent virologic criteria, 10/61 (sixteen.4%) children remaining in follow-up achieved and sustained VL of target not detected (TND) without any rebounds higher up this level. Half dozen of these 10 children were also e'er diagnostic PCR negative (Table iv). Three of x met the report immunologic criteria. Individual plots of VL and CD4 response of representative children are shown in Fig. iii.

Table 4 Proportion of 61 HIV-infected infants starting antiretroviral therapy (Fine art) inside xiv days of birth surviving in follow-up who met more than stringent virologic endpoints past age at ART initiation.

Characteristic	Total			Initiated Fine art <48 h			Initiated ART 2 to fourteen days			p-value
	N	% of 61 in follow-up (95% CI)	n/N (%) in sub-group	North	% of 35 in follow-up (95% CI)	northward/North (%) in sub-group	N	% of 26 in follow-up (95% CI)	n/N (%) in sub-group
Did not achieve "Target not detected" (TND) by 48 weeks	25	41.0		13	37.1		12	46.two
Achieved TND and so whatsoever rebound	26	42.six		16	45.7		10	38.5
Sustained TND	10	16.four (8.2–28.one)		half dozen	17.1 (half dozen.6–33.7)		4	11.1 (four.iv–34.9)		1.000
Ever PCR negative	fourteen	23.0 (13.two–35.v)		ten	28.6 (14.6–46.3)		4	xv.4 (4.4–34.nine)		0.357
Non-transient PCR negative	nine	xiv.8 (7.0–26.two)		half dozen	17.ane (half dozen.half-dozen–33.7)		three	11.v (ii.5–30.two)		0.720
Non-transient PCR negative in achieved & sustained <l copies/ml grouping	9		9/32 (28.1)	6		vi/eighteen (33.3)	3		3/14 (21.4)
Non-transient PCR negative in achieved & sustained TND group	five		5/10 (50.0)	4		iv/6 (66.7)	1		1/iv (25.0)

Abbreviations: Antiretroviral treatment (ART), Conviction intervals (CI), Target not detected (TND), polymerase concatenation reaction (PCR).

• Open table in a new tab

Fig. 3 Individual plots of viral load and CD4+ T-jail cell response to antiretroviral therapy of x children in the study. P indicates the timing of positive, I indeterminate and N negative diagnostic PCR tests. A: Children who accomplished and sustained target not detected and sustained CD4% >thirty% (3/61) B: Children who accomplished and sustained target not detected but did not sustain CD4% >30% (seven/61) C: Children who achieved and sustained <50 copies/ml and sustained CD4% >30% (thirteen/61) D: Children who accomplished and sustained <50 copies/ml but did non sustain CD4% >30% (9/61) E: Children who achieved <l copies/ml but did not sustain this level (rebounded) and sustained CD4% >thirty% (6/61) F: Children who achieved <50 copies/ml merely did not sustain this level (rebounded) and did non sustain CD4% >30% (8/61) G: Children who achieved and sustained <400 copies/ml just did not reach <50 copies/ml and sustained CD4% >30% (one/61) H: Children who accomplished and sustained <400 copies/ml simply did not attain <50 copies/ml but did not sustain CD4% >30% (i/61) I: Children who did non achieve <400 copies/ml (failure) but sustained CD4% >thirty% (iii/61) J: Children who did not achieve <400 copies/ml (failure) and did not sustain CD4% >30% (x/61).

• View Big Image
• Figure Viewer
• Download Hi-res image
• Download (PPT)

Fig. iii Individual plots of viral load and CD4+ T-cell response to antiretroviral therapy of ten children in the study. P indicates the timing of positive, I indeterminate and Northward negative diagnostic PCR tests. A: Children who achieved and sustained target non detected and sustained CD4% >xxx% (3/61) B: Children who achieved and sustained target not detected but did not sustain CD4% >xxx% (7/61) C: Children who achieved and sustained <fifty copies/ml and sustained CD4% >30% (13/61) D: Children who accomplished and sustained <50 copies/ml but did not sustain CD4% >30% (nine/61) Due east: Children who achieved <50 copies/ml but did not sustain this level (rebounded) and sustained CD4% >30% (6/61) F: Children who achieved <50 copies/ml but did non sustain this level (rebounded) and did non sustain CD4% >30% (8/61) 1000: Children who achieved and sustained <400 copies/ml but did not reach <50 copies/ml and sustained CD4% >30% (1/61) H: Children who achieved and sustained <400 copies/ml but did not reach <50 copies/ml simply did non sustain CD4% >thirty% (1/61) I: Children who did not accomplish <400 copies/ml (failure) only sustained CD4% >30% (3/61) J: Children who did non achieve <400 copies/ml (failure) and did non sustain CD4% >30% (x/61).

• View Large Image
• Figure Viewer
• Download Hi-res paradigm
• Download (PPT)

4. Discussion

The written report was designed at a time when optimism nigh the potential of early Fine art in neonates to facilitate remission was loftier. We observed that less than a quarter of confirmed HIV-infected early-treated neonates remained in follow-up and met the virologic and immunologic criteria predefined as minimum thresholds to consider Fine art intermission. Nearly half attained the virologic criteria (sustained VL <50 copies/ml); and the eligible proportion was further reduced when the immunologic criteria (sustained CD4+ T-cell percentage >30%) was applied. We concluded that too few infants met the entry criteria for the ATI trial, equally we had originally designed it, to justify its implementation. Alternate designs of trials may even so be scientifically meaningful for this population or subsets thereof. For example, the IMPAACT P1115 protocol defined highly stringent virologic entry criteria including sustained absenteeism of all detectable virus [

[12]

IMPAACT P1115 protocol: very early on intensive handling of HIV-infected infants to attain remission: a stage I/Ii proof of concept study. 2018; (accessed 12 November 2019).

• Google Scholar

].

While the protocol immune initiation of ART inside 14 days of nascency, it was designed to encourage Fine art initiation within 48 h of birth. An on-site, indicate-of-intendance, diagnostic testing program was established to facilitate Fine art initiation earlier discharge after nativity. On-site testing was challenging and coverage of testing only slightly exceeded fifty% [

]. Lack of total testing coverage provided an excellent opportunity to compare infants starting Art <48 h to those starting slightly later. While these comparisons are vulnerable to potential confounders, as timing of ART initiation was non assigned past study design, the major reason for the time of Fine art initiation was based on the reach of the testing plan. There was a slight excess of preterm and low birth weight infants in the later treated group most probable due to operational challenges ensuring acceptable testing coverage of higher chance infants admitted to the hospital neonatal unit of measurement. We would have expected this to bias towards worse outcomes in the afterward treated group. Nevertheless, we observed no significant differences in the protocol-specified virologic and immunologic endpoints past the timing of Fine art initiation.

Lack of apparent benefits of very early Fine art on viral suppression may, at offset glance, appear to contradict previous studies [

]. However, prior studies considered the timing of ART in much wider age bands than examined hither [

]. Moreover, maternal Art was in place before birth in about 80% of the participants, and all infants received nevirapine prophylaxis at birth regardless of the fourth dimension of ART initiation. Drug resistance is unlikely to explicate the findings as all were switched to a ritonavir-lopinavir-based regimen. While studies of acutely infected adults have the reward of being able to classify into Feibig stages and, depending on behavioural factors, potentially fifty-fifty know the exact date of infection, cognition of the precise timing of infection in infants is not possible. Our report was bars to presumed intrauterine-infected neonates; who by and large accept a worse prognosis than infants with intrapartum or post-natally-acquired infection [

[15]

• Marston M.
• Becquet R.
• Zaba B.
• Moulton Fifty.H.
• Gray Thousand.
• Coovadia H.
• et al.

Internet survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa.

• Crossref
• PubMed
• Scopus (109)
• Google Scholar

]. Although intrauterine infection is thought to mainly occur late in pregnancy [

[xvi]

• Rouzioux C.
• Costagliola D.
• Burgard K.
• Blanche South.
• Mayaux M.J.
• Griscelli C.
• Valleron A.J.

Estimated timing of female parent-to-child human immunodeficiency virus type 1 (HIV-i) transmission by use of a Markov model. The HIV infection in newborns french collaborative study group.

• Crossref
• PubMed
• Scopus (221)
• Google Scholar

], historic period is only a crude proxy for duration of infection and high maternal ART coverage may have led to over-representation of intrauterine infections occurring earlier in pregnancy. Thus, fifty-fifty ART started within hours of nascency may be besides tardily in relation to the true timing of infection. Among birth-tested infants, intrauterine-acquired infection predominates in the era of effective antiretroviral prevention of manual, lack of benefit in this grouping is a major limitation of this strategy.

Viral suppression rates, specially to more than stringent cut-offs than required by our protocol were lower than expected. This is virtually likely explained by the pregnant challenges of adequate adherence with ART in neonates and infants. Most of the study participants' caregivers live in impoverished economic circumstances with complex social problems and experience a high degree of HIV-related stigma. This social profile is probable representative of transmitters in an era of high maternal Fine art coverage. Moreover, there are major applied difficulties of sustaining adherence with twice-daily, poorly-palatable liquids for infants.

Mortality was simply observed in those initiating ART <48 h of nativity, however sample size was minor and compunction before Fine art initiation may counter-balance this apparent excess.

Almost half of the early-treated neonates did not achieve the protocol-specified immunologic criteria required for entry into the ATI trial; fifty-fifty amid those who attained the protocol-specified virologic criteria. Discordance in virologic and immunologic response to Fine art in children has been described [

17

• Kelly C.
• Gaskell K.Thousand.
• Richardson Chiliad.
• Klein N.
• Garner P.
• MacPherson P.

Discordant immune response with antiretroviral therapy in HIV-1: a systematic review of clinical outcomes.

• Crossref
• PubMed
• Scopus (25)
• Google Scholar

,

xviii

• Krogstad P.
• Patel M.
• Karalius B.
• Hazra R.
• Abzug Thousand.J.
• Oleske J.
• et al.

Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents.

• Crossref
• PubMed
• Scopus (13)
• Google Scholar

,

19

European Pregnancy and Paediatric HIV Accomplice Collaboration (EPPICC) study group in EuroCoord
Prevalence and clinical outcomes of poor immune response despite virologically suppressive antiretroviral therapy amongst children and adolescents with HIV in Europe and Thailand: cohort study.

• Google Scholar

]. Reported frequency of discordance in other cohorts is lower than nosotros observed just differences in definitions makes comparisons hard [

17

• Kelly C.
• Gaskell K.M.
• Richardson M.
• Klein North.
• Garner P.
• MacPherson P.

Discordant immune response with antiretroviral therapy in HIV-i: a systematic review of clinical outcomes.

• Crossref
• PubMed
• Scopus (25)
• Google Scholar

,

xviii

• Krogstad P.
• Patel K.
• Karalius B.
• Hazra R.
• Abzug 1000.J.
• Oleske J.
• et al.

Incomplete immune reconstitution despite virologic suppression in HIV-ane infected children and adolescents.

• Crossref
• PubMed
• Scopus (thirteen)
• Google Scholar

,

19

European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord
Prevalence and clinical outcomes of poor allowed response despite virologically suppressive antiretroviral therapy among children and adolescents with HIV in Europe and Thailand: cohort written report.

• Google Scholar

]. Unless liberal cut-offs on CD4+ T-cell count had been used, an immunologic endpoint based on count rather than percentage would not have been meaningfully different.

Two recent case reports of long-term remission are of interest, although, in both cases ART was not started in the neonatal menstruum as in our study [

[20]

• Frange P.
• Faye A.
• Avettand-Fenoel Five.
• Bellaton East.
• Descamps D.
• Angin Thousand.
• et al.

HIV-one virological remission lasting more than than 12 years afterward interruption of early on antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a instance study.

• Summary
• Full Text
• Full Text PDF
• PubMed
• Scopus (87)
• Google Scholar

,

[21]

• Violari A.
• Cotton M.F.
• Kuhn Fifty.
• Schramm D.B.
• Paximadis Thou.
• Loubser S.
• Tiemessen C.T.
• et al.

A child with perinatal HIV infection and long-term sustained virological command following antiretroviral treatment abeyance.

• Crossref
• PubMed
• Scopus (31)
• Google Scholar

]. Given that critical host and viral factors very probable contributed to remission in these cases, they support the findings from our report that early handling on its own may non exist sufficient. Moreover, in the one instance, where a denominator could be ascertained, remission was attained in only one child out of more than 200 children who initiated ART reasonably early and interrupted Fine art [

[21]

• Violari A.
• Cotton G.F.
• Kuhn L.
• Schramm D.B.
• Paximadis M.
• Loubser S.
• Tiemessen C.T.
• et al.

A child with perinatal HIV infection and long-term sustained virological control following antiretroviral handling cessation.

• Crossref
• PubMed
• Scopus (31)
• Google Scholar

]. The apparent rarity of post-treatment command supports our decision that very early on ART on its own, with routinely-available regimens, is unlikely to lead to remission in a sizable minority of early-treated infants.

The major limitation of our study is that early antiretroviral therapy for infants is entirely reliant on maternal adherence. Although we supported adherence through an experienced, multi-disciplinary team, the challenges of sustained adherence probable contribute to the results. A second limitation is that we advised use of antiretroviral regimens and formulations that we considered best for this historic period group available in this setting at the time the study was designed. Other alternatives, including raltegravir which was only approved for use in this age group when the study was well-nigh complete [

[22]

• Clarke D.F.
• Penazzato One thousand.
• Capparelli E.
• Cressey T.R.
• Siberry Thou.
• Sugandhi North.
• Mirochnick M.

Prevention and treatment of HIV infection in neonates: testify base for existing WHO dosing recommendations and implementation considerations.

• Crossref
• PubMed
• Scopus (11)
• Google Scholar

], may be more effective. Although raltegravir addresses palatability issues associated with lopinavir-ritonavir, information technology adds a layer of complication effectually preparation for neonates and immature infants. Thus raltegravir offers but minor respite from the adherence challenges which likely drive the poor response to early Fine art. Further research on possible long-acting formulations is needed. The virological and immunological outcomes occurred less often than expected necessitating longer recruitment. Withal, there were no other deviations from the original protocols.

Decisions almost how quickly to offset ART should be based on expectations about the capacity of ART to achieve standard clinical outcomes i.eastward. sustained viral suppression, and reduced morbidity and mortality rather than with the expectation that remission might be attained. Early initiation of more strong antiretroviral regimens or long-acting formulations that can accost adherence challenges and/or alternative interventions, such every bit broadly neutralizing antibodies, need to exist investigated to enable more than rapid and sustained viral control and immune recovery as a stepping stone to achieving remission in this population.

Declaration of Competing Interest

Drs. Kuhn, Technau and Coovadia written report receiving grants from NIH.

Dr. Abrams and Patel study receiving grants from NICHD.

Dr. Burke reports receiving grants from the Eunice Kennedy Shriver National Establish of Child Wellness and Human Development/National Institute of Allergy and Infectious Disease, National Institutes of Health.

Dr. Tiemessen reports receiving grants from the NIH and the South African Enquiry Chairs Initiative of the Department of Scientific discipline and Technology and National Research Foundation.

The other authors have cypher to disclose.

Acknowledgements

Nosotros would like to thank the members of the Data Safety and Monitoring Board including Drs.

Jintanat Ananworanich, Marc Bulterys, Mark Cotton, Jane Lindsey, Mike McCune, and Andrew Prendergast. We would likewise like to thank other members of the study team: Drs. Martie Conradie, Ndileka Mbete, Pamela Murnane and Devasena Gnanashanmugam. The study was supported in part by the Eunice Kennedy Shriver National Found of Child Wellness and Human Development/ National Establish of Allergy and Infectious disease , National Institutes of Health ( U01HD080441 ), USAID/PEPfAR, the South African National HIV Plan, and South African Enquiry Chairs Initiative of the Department of Science and Technology and National Research Foundation of South Africa. Cepheid provided cartridges at discounted prices and loan of machines and technical support. We gratefully acknowledge the infants and families who participated in the study as well as the hard-working report team.

Role of the funding source

Representatives from the NIH were involved in the blueprint of the study, in oversight of its implementation and contributed to the writing of this manuscript. None of the other funders played any part in the writing of this manuscript or the determination to submit for publication.

Appendix. Supplementary materials

References

1. [1].
   • Saez-Cirion A.
   • Bacchus C.
   • Hocqueloux Fifty.
   • Avettand-Fenoel V.
   • Girault I.
   • Lecuroux C.
   • et al.

   Post-treatment HIV-1 controllers with a long-term virological remission after the pause of early initiated antiretroviral therapy ANRS visconti study.

   PLoS Pathog. 2013; ix e1003211
2. [2].
   • Stohr W.
   • Fidler S.
   • McClure M.
   • Weber J.
   • Cooper D.
   • Ramjee M.
   • et al.

   Duration of HIV-ane viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.

   PLoS ONE. 2013; eight : e78287
3. [3].
   • Williams J.P.
   • Hurst J.
   • Stohr W.
   • Robinson N.
   • Dark-brown H.
   • Fisher M.
   • et al.

   HIV-1 DNA predicts disease progression and postal service-treatment virological control.

   Elife. 2014; three : e03821
4. [4].
   • Lodi S.
   • Meyer L.
   • Kelleher A.D.
   • Rosinska Thou.
   • Ghosn J.
   • Sannes M.
   • et al.

   Immunovirologic control 24 months later on intermission of antiretroviral therapy initiated close to HIV seroconversion.

   Curvation Intern Med. 2012; 172 : 1252-1255
5. [5].
   • Steingrover R.
   • Pogany Thousand.
   • Fernandez Garcia Due east.
   • Jurriaans S.
   • Brinkman G.
   • Schuitemaker H.
   • et al.

   HIV-1 viral rebound dynamics after a single treatment break depends on time of initiation of highly agile antiretroviral therapy.

   AIDS. 2008; 22 : 1583-1588
6. [half dozen].
   • Namazi G.
   • Fajnzylber J.M.
   • Aga E.
   • Bosch R.J.
   • Acosta Due east.P.
   • Sharaf R.
   • et al.

   The control of hiv after antiretroviral medication pause (Gnaw) study: posttreatment controllers identified from fourteen clinical studies.

   J Infect Dis. 2018; 218 : 1954-1963
7. [vii].
   • Persaud D.
   • Gay H.
   • Ziemniak C.
   • Chen Y.H.
   • Piatak Jr., M.
   • Chun T.West.
   • et al.

   Absenteeism of detectable HIV-i viremia after treatment cessation in an infant.

   Northward Engl J Med. 2013; 369 : 1828-1835
8. [8].
   • Tobin N.H.
   • Aldrovandi G.1000.

   Are infants unique in their power to exist "functionally cured" of HIV-1?.

   Curr HIV/AIDS Rep. 2014; 11 : 1-10
9. [ix].
   • Goulder P.J.
   • Lewin S.R.
   • Leitman E.M.

   Paediatric hiv infection: the potential for cure.

   Nat Rev Immunol. 2016; 16 : 259-271
10. [10].
    • Technau One thousand.Yard.
    • Kuhn Fifty.
    • Coovadia A.
    • Murnane P.Chiliad.
    • Sherman G.

    Xpert HIV-1 bespeak-of-care examination for neonatal diagnosis of hiv in the birth testing programme of a maternity hospital: a field evaluation written report.

    The Lancet HIV. 2017; 4 : e442-e4e8
11. [11].
    • Avettand-Fenoel V.
    • Hocqueloux L.
    • Ghosn J.
    • Cheret A.
    • Frange P.
    • Melard A.
    • Viard J.P.
    • Rouzioux C.

    Full HIV-one Dna, a marking of viral reservoir dynamics with clinical implications.

    Clin Microbiol Rev. 2016; 29 : 859-880
12. [12].

    IMPAACT P1115 protocol: very early intensive treatment of HIV-infected infants to achieve remission: a phase I/II proof of concept study. 2018; (accessed 12 November 2019).

13. [xiii].
    • Violari A.
    • Cotton M.F.
    • Gibb D.Grand.
    • Babiker A.M.
    • Steyn J.
    • Madhi S.A.
    • et al.

    Early antiretroviral therapy and bloodshed among HIV-infected infants.

    N Engl J Med. 2008; 359 : 2233-2244
14. [14].
    • Shiau S.
    • Abrams E.J.
    • Arpadi S.M.
    • Kuhn Fifty.

    Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission?.

    The Lancet HIV. 2018; five : e250-e2e8
15. [15].
    • Marston Thou.
    • Becquet R.
    • Zaba B.
    • Moulton L.H.
    • Gray G.
    • Coovadia H.
    • et al.

    Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa.

    Int J Epidemiol. 2011; forty : 385-396
16. [16].
    • Rouzioux C.
    • Costagliola D.
    • Burgard One thousand.
    • Blanche S.
    • Mayaux M.J.
    • Griscelli C.
    • Valleron A.J.

    Estimated timing of mother-to-child human immunodeficiency virus blazon 1 (HIV-1) transmission by use of a Markov model. The HIV infection in newborns french collaborative written report group.

    Am J Epidemiol. 1995; 142 : 1330-1337
17. [17].
    • Kelly C.
    • Gaskell Grand.M.
    • Richardson M.
    • Klein Due north.
    • Garner P.
    • MacPherson P.

    Discordant allowed response with antiretroviral therapy in HIV-1: a systematic review of clinical outcomes.

    PLoS I. 2016; 11 e0156099
18. [18].
    • Krogstad P.
    • Patel M.
    • Karalius B.
    • Hazra R.
    • Abzug 1000.J.
    • Oleske J.
    • et al.

    Incomplete immune reconstitution despite virologic suppression in HIV-ane infected children and adolescents.

    Aids. 2015; 29 : 683-693
19. [19].
    • European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord

    Prevalence and clinical outcomes of poor immune response despite virologically suppressive antiretroviral therapy amongst children and adolescents with HIV in Europe and Thailand: cohort written report.

    Clin Infect Dis. 2019; ()
20. [twenty].
    • Frange P.
    • Faye A.
    • Avettand-Fenoel V.
    • Bellaton E.
    • Descamps D.
    • Angin M.
    • et al.

    HIV-1 virological remission lasting more than 12 years after suspension of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.

    The Lancet HIV. 2016; 3 : e49-e54
21. [21].
    • Violari A.
    • Cotton K.F.
    • Kuhn L.
    • Schramm D.B.
    • Paximadis M.
    • Loubser S.
    • Tiemessen C.T.
    • et al.

    A kid with perinatal HIV infection and long-term sustained virological command post-obit antiretroviral treatment abeyance.

    Nat Commun. 2019; 10 : 412
22. [22].
    • Clarke D.F.
    • Penazzato M.
    • Capparelli East.
    • Cressey T.R.
    • Siberry G.
    • Sugandhi Due north.
    • Mirochnick 1000.

    Prevention and treatment of HIV infection in neonates: show base for existing WHO dosing recommendations and implementation considerations.

    Skilful Rev Clin Pharmacol. 2018; 11 : 83-93

Article Info

Publication History

Published: January 08, 2020

Accustomed: Dec 11, 2019

Received in revised grade: November 27, 2019

Received: August 18, 2019

Identification

DOI: https://doi.org/10.1016/j.eclinm.2019.100241

Copyright

© 2022 Published by Elsevier Ltd.

User License

Artistic Commons Attribution – NonCommercial – NoDerivs (CC By-NC-ND 4.0) |

How you tin reuse

Permitted

For not-commercial purposes:

• Read, print & download
• Redistribute or republish the final article
• Text & data mine
• Interpret the article (private use but, not for distribution)
• Reuse portions or extracts from the commodity in other works

Not Permitted

• Sell or re-use for commercial purposes
• Distribute translations or adaptations of the article

Elsevier'southward open access license policy

ScienceDirect

Access this article on ScienceDirect

• View Big Image
• Download Hi-res image
• Download .PPT

riveraageres.blogspot.com

Source: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(19)30246-9/fulltext

Share this post